Is SABS or SLDB more undervalued in 2026?

CirclFi compares SAB Biotherapeutics, Inc. (SABS) and Solid Biosciences Inc. (SLDB) using 13 institutional-grade valuation models. SABS has a Quality of Company score of 5.0/10 while SLDB scores 4.4/10.

Which is a better buy — SABS or SLDB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SABS and SLDB valuations compare?

SABS at $3.60 and SLDB at $7.34 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SABS vs SLDB Valuation Comparison 2026 — Intrinsic Value Analysis

SABS

Biological Products, (No Diagnostic Substances)

SAB Biotherapeutics, Inc.

Quality

5.0

out of 10

Value Trap

WARN

Price

$3.60

Last close

Models

12/13

Active

SLDB

Biological Products, (No Diagnostic Substances)

Solid Biosciences Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$7.34

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	SABS Fair Value	SABS Upside	SLDB Fair Value	SLDB Upside
Bayesian DCF	Intrinsic	$1.27	-64.8%	$3.30	-55.1%
Earnings Power Value	Intrinsic	$6.17	+77.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.90	-47.2%	$4.75	-35.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SABS vs SLDB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SABS vs SLDB — Which Stock Is More Undervalued?

SABS scores higher with a 5.0/10 quality rating vs SLDB's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SAB Biotherapeutics, Inc. (SABS) and Solid Biosciences Inc. (SLDB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SABS currently trades at $3.60 with a QOC of 5.0/10, while SLDB trades at $7.34 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).